Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Alirocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), has been shown to reduce low-density lipoprotein (LDL) cholesterol levels in patients who are receiving statin therapy. Larger and longer-term studies are needed to establish safety and efficacy. METHODS: We conducted a randomized trial involving 2341 patients at high risk for cardiovascular events who had LDL cholesterol levels of 70 mg per deciliter (1.8 mmol per liter) or more and were receiving treatment with statins at the maximum tolerated dose (the highest dose associated with an acceptable side-effect profile), with or without other lipid-lowering therapy. Patients were randomly assigned in a 2:1 ratio to receive alirocumab (150 mg) or placebo as a 1-ml subcutaneous injection every 2 weeks for 78 weeks. The primary efficacy end point was the percentage change in calculated LDL cholesterol level from baseline to week 24. RESULTS: At week 24, the difference between the alirocumab and placebo groups in the mean percentage change from baseline in calculated LDL cholesterol level was -62 percentage points (P<0.001); the treatment effect remained consistent over a period of 78 weeks. The alirocumab group, as compared with the placebo group, had higher rates of injection-site reactions (5.9% vs. 4.2%), myalgia (5.4% vs. 2.9%), neurocognitive events (1.2% vs. 0.5%), and ophthalmologic events (2.9% vs. 1.9%). In a post hoc analysis, the rate of major adverse cardiovascular events (death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization) was lower with alirocumab than with placebo (1.7% vs. 3.3%; hazard ratio, 0.52; 95% confidence interval, 0.31 to 0.90; nominal P=0.02). CONCLUSIONS: Over a period of 78 weeks, alirocumab, when added to statin therapy at the maximum tolerated dose, significantly reduced LDL cholesterol levels. In a post hoc analysis, there was evidence of a reduction in the rate of cardiovascular events with alirocumab. (Funded by Sanofi and Regeneron Pharmaceuticals; ODYSSEY LONG TERM ClinicalTrials.gov number, NCT01507831.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The efficacy at reducing LDL-C is in the range of 50-70%, independent of the presence of a background therapy (statins, ezetimibe, etc.); preliminary data from phase 3 trials suggest a reduction of CV events in line with the LDL-C reduction achieved.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [115]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the initial trials of these drugs, the incidence of neurocognitive adverse events (including delirium, cognitive and attentional disturbances, dementia, thought and perceptual disturbances, and psychiatric disorders) was very low (<1%) but slightly higher albeit non-significantly in the treated groups compared with placebo (0.9% vs. 0.3% for evolocumab) (81) (1.2% vs. 0.5% for alirocumab) (82).”
From PCSK9 and the nervous system: a no-brainer? (2023) · cites this paper as [81]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“alirocumab, a PCSK9 monoclonal antibody in clinical use (Robinson et al., 2015)”
From γ-secretase inhibition lowers plasma triglyceride-rich lipoproteins by stabilizing the LDL receptor (2018) · cites this paper as Robinson et al., 2015
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Data from the GLAGOV, ODYSSEY COMBO I and ODYSSEY LONG TERM trials show greater efficacy of PCSK9 inhibitors in patients with prior CVD (or myocardial infarction) in terms of LDL-C and percent atheroma volume [86–88].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [88]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The beneficial effect of ezetimibe is also supported by genetic studies of mutations in NPC1L1; naturally occurring mutations that inactivate the protein were found to be associated with reduced plasma LDL-C and reduced risk for CAD [55,269,270].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [270]
Experimental — accuracy not yet measured
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Self-citationNiacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
Effects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668
Cited by
Items 201–300 of 1,019
Danchin, N., Almahmeed, W. A., Al‐Rasadi, K., Azuri, J., BERRAH, A., Cuneo, C. A., Karpov, Y., Kaul, U., Kayıkçıoğlu, M., Mitchenko, O., et al. (2018) · European Journal of Preventive Cardiology · doi:10.1177/2047487318777079 · Cited by 121
“Post hoc data with alirocumab from the ODYSSEY LONG TERM study also suggest cardiovascular benefits.(24) These findings suggest a real therapeutic benefit of non-statin therapies in addition to maximally tolerated LLT in the prevention of cardiovascular events and that lowering LDL-C to levels far below current recomm…”
MethodAnti-atherosclerotic therapies: Milestones, challenges, and emerging innovations
Hetherington, I., & Totary-Jain, H. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.08.024 · Cited by 126
Genetics: Implications for Prevention and Management of Coronary Artery Disease
Assimes, T. L., & Roberts, R. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.10.039 · Cited by 126
“Despite the limited novelty of these findings with respect to mechanisms of disease, they include PCSK9 and NPC1L1, 2 genes with Food and Drug Association–approved drugs on the market that inhibit the activity of the gene’s protein and lead to a reduction of both plasma LDL levels as well as the risk of CAD (106,151,1…”
BackgroundEfficacy and safety of lipid lowering by alirocumab in chronic kidney disease
Toth, P. P., Dwyer, J. P., Cannon, C. P., Colhoun, H. M., Rader, D. J., Upadhyay, A., Louie, M. J., Koren, A., Letierce, A., Mandel, J., et al. (2018) · Kidney International · doi:10.1016/j.kint.2017.12.011 · Cited by 123
Burgess, S. (2018) · Apollo (University of Cambridge) · doi:10.17863/cam.26250 · Cited by 102
Leiter, L. A., Teoh, H., Kallend, D., Wright, R. S., Landmesser, U., Wijngaard, P. L. J., Kastelein, J. J. P., & Ray, K. K. (2019) · Diabetes Care · doi:10.2337/dc18-1491 · Cited by 117
Self-citationTremblay, F., Xiong, Q., Shah, S. S., Ko, C., Kelly, K., Morrison, M. S., Giancarlo, C., Ramírez, R. N., Hildebrand, E. M., Voytek, S. B., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03508-x · Cited by 125
“…demonstrated in preclinical experiments including mice 36 and NHPs 37 and confirmed in multiple clinical settings, irrespective of the mechanism by which reduction of plasma PCSK9 is achieved, such as monoclonal antibodies 32,38 , RNA interference (RNAi) therapeutics 33 or adenine base editor 20 .”
Tavori, H., Giunzioni, I., Predazzi, I. M., Plubell, D. L., Shivinsky, A., Miles, J., DeVay, R. M., Hong, L., Rashid, S., Linton, M. F., et al. (2016) · Cardiovascular Research · doi:10.1093/cvr/cvw053 · Cited by 125
Sahebkar, A., Di Giosia, P., Stamerra, C. A., Grassi, D., Pedone, C., Ferretti, G., Bacchetti, T., Ferri, C., & Giorgini, P. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12905 · Cited by 116
Seidah, N. G., Abifadel, M., Prost, S., Boileau, C., & Prat, A. (2017) · Pharmacological Reviews · doi:10.1124/pr.116.012989 · Cited by 116
“Furthermore, such processing was shown to extend the half-life of a distinct anti-PCSK9 mAb that recognizes the N-terminal sequence aa 168–181, which, different from Evolocumab or Alirocumab, does not sterically impede the inactivating furin cleavage at Arg218↓ (Schroeder et al., 2015).”
BackgroundInfluentialHaas, M. E., Levenson, A. E., Sun, X., Liao, W.-H., Rutkowski, J. M., Nephrotic Syndrome Study Network, de Ferranti, S. D., Schumacher, V., Scherer, P. E., Salant, D. J., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.020912 · Cited by 117
2024 EACTS Guidelines on perioperative medication in adult cardiac surgery
Jeppsson, A., (Sweden), (.-C., Rocca, B., (Italy), (.-C., Hansson, E. C., (Sweden), Guðbjartsson, T., (Iceland), James, S. K., (Sweden), et al. (2024) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezae355 · Cited by 129
Kiyosue, A., Honarpour, N., Kurtz, C., Xue, A., Wasserman, S. M., & Hirayama, A. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.10.021 · Cited by 114
PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) Ex Vivo
Villard, E. F., Thedrez, A., Blankenstein, J., Croyal, M., Tran, T.-T.-T., Poirier, B., Le Bail, J.-C., Illiano, S., Nobécourt, E., Krempf, M., et al. (2016) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2016.06.006 · Cited by 113
“But, unlike statins (6), anti-PCSK9 mAbs also promote an unexplained 25% to 30% reduction in circulating lipoprotein (a) [Lp(a)] levels (1,2,7).”
Self-citationPostprandial hyperglycemia and postprandial hypertriglyceridemia in type 2 diabetes
Hiyoshi, T., Fujiwara, M., & Zemin, Y. (2018) · Journal of Biomedical Research · doi:10.7555/jbr.31.20160164 · Cited by 126
Chinese Guideline on the Primary Prevention of Cardiovascular Diseases
Chinese Society of Cardiology of Chinese Medical Association, C. D. P. A. R. C. O. C. A. O. R. M. (2021) · Cardiology Discovery · doi:10.1097/cd9.0000000000000025 · Cited by 132
Ferri, N., Marchianò, S., Tibolla, G., Baetta, R., Dhyani, A., Ruscica, M., Uboldi, P., Catapano, A. L., & Corsini, A. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.07.910 · Cited by 117
Prevention of Cardiovascular Disease
Reamy, B. V., Williams, P. M., & Kuckel, D. P. (2018) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2017.11.003 · Cited by 128
“The addition of one of these medications to a statin can lower LDL an additional 50% to 60%.(49,50) Patients on pharmacologic therapy should have lipid levels re-evaluated at 12 weeks with a focused medical history to assess compliance with medication and lifestyle changes.”
BackgroundCoronary Artery Disease Genetics Enlightened by Genome-Wide Association Studies
Kessler, T., & Schunkert, H. (2021) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2021.04.001 · Cited by 123
Potential therapeutic effects of mTOR inhibition in atherosclerosis
Kurdi, A., Meyer, G. R. Y. D., & Martinet, W. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12820 · Cited by 113
PCSK9 Inhibition: From Current Advances to Evolving Future
Liu, C., Chen, J., Chen, H., Zhang, T., He, D., Luo, Q., Chi, J., Hong, Z., Liao, Y., Zhang, S., et al. (2022) · Cells · doi:10.3390/cells11192972 · Cited by 119
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
Michaeli, D. T., Michaeli, J. C., Albers, S., Boch, T., & Michaeli, T. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00594-5 · Cited by 109
Metabolomic Consequences of Genetic Inhibition of PCSK9 Compared With Statin Treatment
Sliz, E., Kettunen, J., Holmes, M. V., Williams, C. O., Boachie, C., Wang, Q., Männikkö, M., Sebert, S., Walters, R., Lin, K., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.034942 · Cited by 109
Signaling cascades in the failing heart and emerging therapeutic strategies
He, X., Du, T., Long, T., Liao, X., Dong, Y., & Huang, Z. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00972-6 · Cited by 113
“Targeting PCSK9 with blocking antibodies in addition to standard therapy lowers LDL-C levels and reduces cardiovascular risk.(486,487) Inclisiran is a synthetic siRNA against PCSK9 mRNA.”
BackgroundMark, H. (2017) · doi:10.1016/j.jacc.2017.10.001 · Cited by 107
“Initial studies in humans confirmed the striking power of PCSK9 inhibitors to lower LDL-C levels, with few reported adverse effects (4,5).”
BackgroundManagement of patients with familial hypercholesterolaemia
Reiner, Ž. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.92 · Cited by 115
Han, X. B., Li, H. X., Jiang, Y., Wang, H., Li, X. S., Kou, J., Zheng, Y., Liu, Z. N., Li, H., Li, J., et al. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.242 · Cited by 108
Ray, K. K., Leiter, L. A., Müller‐Wieland, D., Cariou, B., Colhoun, H. M., Henry, R. R., Tinahones, F. J., Bujas‐Bobanovic, M., Domenger, C., Letierce, A., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13257 · Cited by 107
Age at onset in genetic prion disease and the design of preventive clinical trials
Minikel, E. V., Vallabh, S. M., Orseth, M. C., Brandel, J., Haïk, S., Laplanche, J., Zerr, I., Parchi, P., Capellari, S., Safar, J., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007745 · Cited by 106
A Comprehensive Review of PCSK9 Inhibitors
Coppinger, C., Movahed, M. R., Azemawah, V., Peyton, L., Gregory, J., & Hashemzadeh, M. (2022) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484221100107 · Cited by 109
“Adverse events were comparable to trials with evolocumab.(39) The ODYSSEY OUTCOMES trial evaluated the effect of alirocumab on patients who had ACS in the 1 to 12 months prior to enrollment with similar results.”
ResultA systematic review of PCSK9 inhibitors alirocumab and evolocumab
McDonagh, M., Peterson, K., Holzhammer, B., & Fazio, S. (2016) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2016.22.6.641 · Cited by 103
“0).(20,30) The difference in the percentage of reduction in LDL-C and HDL-C was also greater.”
BackgroundStroes, E. S. G., Guyton, J. R., Lepor, N. E., Civeira, F., Gaudet, D., Watts, G. F., Baccara‐Dinet, M. T., Lecorps, G., Manvelian, G. Z., Farnier, M., et al. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.003421 · Cited by 108
Self-citationOrringer, C. E., Jacobson, T. A., Saseen, J. J., Brown, A. S., Gotto, A. M., Ross, J. L., & Underberg, J. A. (2017) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2017.05.001 · Cited by 100
“In 2015, a safety and efficacy trial of the PCSK9 inhibitor, alirocumab (ODYSSEY LONG TERM), enrolled 2341 adult subjects aged $18 years at high risk for cardiovascular events based on the presence of heterozygous FH (HeFH), established coronary heart disease (CHD), or coronary risk equivalent states.(4) A coronary ri…”
BackgroundCan LDL cholesterol be too low? Possible risks of extremely low levels
OLSSON, A. G., Angelin, B., Assmann, G., Binder, C. J., Björkhem, I., Cedazo-Mínguez, Á., Cohen, J. C., von Eckardstein, A., Farinaro, E., Müller‐Wieland, D., et al. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12614 · Cited by 114
Petersen, D. N., Hawkins, J., Ruangsiriluk, W., Stevens, K. A., Maguire, B. A., O’Connell, T. N., Rocke, B. N., Boehm, M., Ruggeri, R. B., Rolph, T., et al. (2016) · Cell chemical biology · doi:10.1016/j.chembiol.2016.08.016 · Cited by 107
Oestrogen-modulated gene expression in the human endometrium
Punyadeera, C., Dassen, H. H. N. M., Klomp, J. P. G., Dunselman, G. A. J., Kamps, R., Dijcks, F. A., EDERVEEN, A. G. H., de Goeij, A. F. P. M., & Groothuis, P. G. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4435-y · Cited by 107
PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety
Roth, E. M., & Davidson, M. H. (2018) · Reviews in Cardiovascular Medicine · doi:10.3909/ricm19s1s0002 · Cited by 110
Ahn, G., Banik, S. M., & Bertozzi, C. R. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.02.024 · Cited by 100
“As a result, strategies that inhibit PCSK9 from interacting with LDLR and enable LDLR to lower plasma LDL cholesterol have become approved therapeutics (Robinson et al., 2015; Sheridan, 2015; Sabatine et al., 2015).”
BackgroundPCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future
Shimada, Y. J., & Cannon, C. P. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv174 · Cited by 98
Cholesterol in LDL receptor recycling and degradation
Yang, H.-X., Zhang, M., Long, S.-Y., Tuo, Q.-H., Tian, Y., Chen, J.-X., Zhang, C.-P., & Liao, D.-F. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.09.022 · Cited by 98
van Poelgeest, E. P., Hodges, M. R., Moerland, M., Tessier, Y., Levin, A. A., Persson, R., Lindholm, M. W., Dumong Erichsen, K., Ørum, H., Cohen, A. F., et al. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12738 · Cited by 93
Current therapies for lowering lipoprotein (a)
van Capelleveen, J. C., van der Valk, F. M., & Stroes, E. S. G. (2015) · Journal of Lipid Research · doi:10.1194/jlr.r053066 · Cited by 102
Self-citationPCSK9 promotes tumor growth by inhibiting tumor cell apoptosis in hepatocellular carcinoma
Zhang, S.-Z., Zhu, X., Feng, L.-H., Li, X., Liu, X., Sun, H., & Tang, Z. (2021) · Experimental Hematology and Oncology · doi:10.1186/s40164-021-00218-1 · Cited by 97
The perils of surrogate endpoints
Weintraub, W. S., Lüscher, T. F., & Pocock, S. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv164 · Cited by 110
Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials
Jones, P. H., Bays, H. E., Chaudhari, U., Pordy, R. C., Lorenzato, C., Miller, K., & Robinson, J. G. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.08.072 · Cited by 100
“02), primarily because of their inclusion of the 2 large, long-term trials of both drugs.(8,19,20) However, this meta-analysis only included 2 alirocumab phase 3 studies (LONG TERM and COMBO I), whereas our pooled analysis includes 14 trials.”
BackgroundSelf-citationPhysiological and therapeutic regulation of PCSK9 activity in cardiovascular disease
Glerup, S., Schulz, R., Laufs, U., & Schlüter, K. (2017) · Basic Research in Cardiology · doi:10.1007/s00395-017-0619-0 · Cited by 101
The cargo receptor SURF4 promotes the efficient cellular secretion of PCSK9
Emmer, B. T., Hesketh, G. G., Kotnik, E., Tang, V. T., Lascuna, P. J., Xiang, J., Gingras, A.-C., Chen, X.-W., & Ginsburg, D. (2018) · eLife · doi:10.7554/elife.38839 · Cited by 96
Epidemiology of Dementia: The Burden on Society, the Challenges for Research
Wolters, F. J., & Ikram, M. A. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7704-8_1 · Cited by 106
Abu‐Assi, E., López-López, A., Salvado, V. G., Diéguez, A. R., Peña, C., Bouzas‐Cruz, N., Raposeiras‐Roubín, S., Abumuaileq, R. R.-Y., García‐Acuña, J. M., & González‐Juanatey, J. R. (2015) · Revista Española de Cardiología · doi:10.1016/j.recesp.2015.06.016 · Cited by 94
O’Connell, E. M., & Lohoff, F. W. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00609 · Cited by 93
Annemans, L., Packard, C. J., Briggs, A., & Ray, K. K. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx710 · Cited by 89
Karagiannis, A. D., Liu, M., Toth, P. P., Zhao, S., Agrawal, D. K., Libby, P., & Chatzizisis, Y. S. (2018) · Current Atherosclerosis Reports · doi:10.1007/s11883-018-0718-x · Cited by 99
In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model
Carreras, A., Pane, L. S., Nitsch, R., Madeyski-Bengtson, K., Porritt, M., Akcakaya, P., Taheri-Ghahfarokhi, A., Ericson, E., Bjursell, M., Perez-Alcazar, M., et al. (2019) · BMC Biology · doi:10.1186/s12915-018-0624-2 · Cited by 91
PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
Katzmann, J. L., Gouni-Berthold, I., & Laufs, U. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.595819 · Cited by 87
“Patients enrolled in any one of the 12 studies of the evolocumab study program could be included in the open-label extension studies OSLER-1 (phase 2 studies) and OSLER-2 (phase 3 studies) (Sabatine et al., 2015).”
BackgroundToth, P. P., Worthy, G., Gandra, S. R., Sattar, N. A., Bray, S. L., Cheng, L., Bridges, I. M., Worth, G. M., Dent, R. E., Forbes, C. A., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.005367 · Cited by 101
Self-citationEvidence-based goals in LDL-C reduction
Soran, H., Dent, R., & Durrington, P. (2017) · Clinical Research in Cardiology · doi:10.1007/s00392-016-1069-7 · Cited by 92
Adverse Events Associated With PCSK 9 Inhibitors: A Real‐World Experience
Gürgöze, M. T., Muller‐Hansma, A. H. G., Schreuder, M. M., Galema‐Boers, A. M. H., Boersma, E., & Roeters van Lennep, J. E. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1193 · Cited by 92
“In multiple large randomized placebo- controlled trials, PCSK9 inhibitors showed reductions of LDL- C levels up to 60% and recently also a decrease in cardiovascular outcomes.(8,9) WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? RCTs assessing clinical effects of PCSK9 inhibitors alirocumab and evolocumab showed a favor…”
BackgroundLipoprotein(a) and Risk of Ischemic Stroke in the REGARDS Study
Arora, P. K., Kalra, R., CALLAS, P. W., Alexander, K., Zakai, N. A., Wadley, V. G., Arora, G., D, B. M. K. M., Judd, S. E., & Cushman, M. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311857 · Cited by 98
Afshar, M. S., Pilote, L., Dufresne, L., Engert, J. C., & Thanassoulis, G. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.003012 · Cited by 95
From genetic associations to genes: methods, applications, and challenges
Qi, T., Song, L., Guo, Y., Chen, C., & Yang, J. (2024) · Trends in Genetics · doi:10.1016/j.tig.2024.04.008 · Cited by 104
Management of residual risk after statin therapy
Reith, C. A., & Armitage, J. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.12.018 · Cited by 95
A Therapeutic Peptide Vaccine Against PCSK9
Pan, Y., Zhou, Y., Wu, H., Chen, X., Hu, X., Zhang, H., Zhou, Z., Qiu, Z., & Liao, Y. (2017) · Scientific Reports · doi:10.1038/s41598-017-13069-w · Cited by 94
Apaijai, N., Moisescu, D. M., Palee, S., McSweeney, C. M., Saiyasit, N., Maneechote, C., Boonnag, C., Chattipakorn, N., & Chattipakorn, S. C. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.010838 · Cited by 90
Unmet Needs in LDL-C Lowering: When Statins Won’t Do!
Krähenbühl, S., Pavik-Mezzour, I., & von Eckardstein, A. (2016) · Drugs · doi:10.1007/s40265-016-0613-0 · Cited by 89
Bom, M. J., van der Heijden, D. J., Kedhi, E., der Heyden, J. V., Meuwissen, M., Knaapen, P., Timmer, S. A. J., & van Royen, N. (2017) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.116.005973 · Cited by 95
Harvey, P. D., Sabbagh, M. N., Harrison, J., Ginsberg, H. N., Chapman, M. J., Manvelian, G. Z., Moryusef, A., Mandel, J., & Farnier, M. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx661 · Cited by 93
Self-citationGragnano, F., & Calabrò, P. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.01.012 · Cited by 90
PCSK9 inhibitors for treating hypercholesterolemia
Pasta, A., Cremonini, A. L., Pisciotta, L., Buscaglia, A., Porto, I., Barra, F., Ferrero, S., Brunelli, C., & Rosa, G. M. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1702970 · Cited by 94
“17), but the incidence did not seem to be associated with the LDL-C levels reached during treatment [51].”
BackgroundLow levels of low-density lipoprotein cholesterol and cognitive decline
Hua, R., Ma, Y., Li, C., Zhong, B., & Xie, W. (2021) · 中国科学通报:英文版 · doi:10.1016/j.scib.2021.02.018 · Cited by 93
Statin-associated muscle symptoms—Managing the highly intolerant
Backes, J. M., Ruisinger, J. F., Gibson, C., & Moriarty, P. M. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.01.006 · Cited by 92
Penson, P. E., Long, D. L., Howard, G., Toth, P. P., Muntner, P., Howard, V. J., Safford, M. M., Jones, S. R., Martin, S. S., Mazidi, M., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy533 · Cited by 93
Apolipoprotein B: Bridging the Gap Between Evidence and Clinical Practice
Oliveira-Gomes, D. D., Joshi, P. H., Peterson, E. D., Rohatgi, A. K., Khera, A., & Návar, A. M. (2024) · Circulation · doi:10.1161/circulationaha.124.068885 · Cited by 101
Handelsman, Y., & Lepor, N. E. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.008953 · Cited by 86
Self-citationPerspectives on Treatment for Nonalcoholic Steatohepatitis
Lassailly, G., Caiazzo, R. J., Pattou, F. N., & Mathurin, P. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.03.004 · Cited by 94
Gandra, S. R., Villa, G., Fonarow, G. C., Löthgren, M., Lindgren, P., Somaratne, R. M., & van Hout, B. (2016) · Clinical Cardiology · doi:10.1002/clc.22535 · Cited by 95
PCSK9 Inhibitors: Mechanisms of Action, Metabolic Effects, and Clinical Outcomes
Hess, C. N., Wang, C. C. L., & Hiatt, W. R. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-042716-091351 · Cited by 93
Human Genetics of Obesity and Type 2 Diabetes Mellitus: Past, Present, and Future
Ingelsson, E., & McCarthy, M. I. (2018) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.118.002090 · Cited by 95
NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations
Niederseer, D., Wernly, B., Aigner, E. S., Stickel, F., & Datz, C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10030467 · Cited by 93
The Treatment of Disorders of Lipid Metabolism
Parhofer, K. G. (2016) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2016.0261 · Cited by 104
Experimental and clinical pharmacology: PCSK9 inhibitors - mechanisms of action
Page, M. M., & Watts, G. F. (2016) · Australian Prescriber · doi:10.18773/austprescr.2016.060 · Cited by 101
Kent, S. T., Rosenson, R. S., Avery, C. L., Chen, Y.-D. I., Correa, A., Cummings, S. R., Cupples, L. A., Cushman, M., Evans, D. S., Gudnason, V., et al. (2017) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.116.001632 · Cited by 86
Management of Dyslipidemia in Patients with Hypertension, Diabetes, and Metabolic Syndrome
Srikanth, S., & DEEDWANIA, P. C. (2016) · Current Hypertension Reports · doi:10.1007/s11906-016-0683-0 · Cited by 99
Progress and perspectives in plant sterol and plant stanol research
Jones, P. J. H., Shamloo, M., MacKay, D., Rideout, T. C., Myrie, S. B., Plat, J., Roullet, J., Baer, D. J., Calkins, K. L., Davis, H. R., et al. (2018) · Nutrition Reviews · doi:10.1093/nutrit/nuy032 · Cited by 95
Duell, P. B., Gidding, S. S., Andersen, R. L., Knickelbine, T., Anderson, L., Gianos, E., Shrader, P., Kindt, I., O'Brien, E. C., McCann, D., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.007 · Cited by 89
DEEDWANIA, P. C., Murphy, S. A., Scheen, A. J., Badarienė, J., Pineda, A. L., Honarpour, N., KEECH, A. C., Sever, P., Pedersen, T. R., Sabatine, M. S., et al. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.3151 · Cited by 89
Treatment Options for Statin-Associated Muscle Symptoms
Laufs, U., Scharnagl, H., Halle, M., Windler, E., Endres, M., & März, W. (2015) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2015.0748 · Cited by 92
Small molecules as inhibitors of PCSK9: Current status and future challenges
Xu, S., Luo, S., Zhu, Z., & Xu, J. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.11.011 · Cited by 85
PCSK9 inhibition in the management of familial hypercholesterolemia
Ogura, M. (2018) · Journal of Cardiology · doi:10.1016/j.jjcc.2017.07.002 · Cited by 84
“Adding an antiPCSK9 antibody to standard therapy with statin alone or statin combined with ezetimibe reportedly further reduced serum LDL-C levels by around 60% and a retrospective analysis found that they halved cardiovascular event incidence as compared with placebo [13,14].”
Evolving targets for the treatment of atherosclerosis
Solanki, A., Bhatt, L. K., & Johnston, T. P. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.02.002 · Cited by 96
“However, there were several nonspecific adverse events such as fatigue, limb pain, and arthralgia (Sabatine et al., 2015).”
BackgroundArrieta, A., Page, T. F., Veledar, E., & Nasir, K. (2017) · PLoS ONE · doi:10.1371/journal.pone.0169761 · Cited by 83
A Versatile Nonviral Delivery System for Multiplex Gene‐Editing in the Liver
Gong, J., Wang, H., Lao, Y., Hu, H., Vatan, N. M., Guo, J., Ho, T., Huang, D., Li, M., Shao, D., et al. (2020) · Advanced Materials · doi:10.1002/adma.202003537 · Cited by 84
Sanz-Cuesta, B. E., & Saver, J. L. (2021) · Stroke · doi:10.1161/strokeaha.121.034576 · Cited by 83
Ferri, N., & Ruscica, M. (2016) · Endocrine · doi:10.1007/s12020-016-0939-0 · Cited by 89
Grado de control lipídico en pacientes coronarios y medidas adoptadas por los médicos. Estudio REPAR
Galve, E., Cordero, A., Cequier, A. R., Ruiz, E., & González‐Juanatey, J. R. (2016) · Revista Española de Cardiología · doi:10.1016/j.recesp.2016.02.013 · Cited by 87
Oesterle, A., & Liao, J. K. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161116666180817155058 · Cited by 92
Tuñón, J., Steg, P. G., Bhatt, D. L., Bittner, V., Díaz, R., Goodman, S. G., Jukema, J. W., Kim, Y.-U., Li, Q. H., Mueller, C. E., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa498 · Cited by 82
Self-citationPCSK9 inhibition as a novel therapeutic target for alcoholic liver disease
Lee, J. S., Mukhopadhyay, P., Mátyás, C., Trojnár, E., Pálóczi, J., Yang, Y. R., Blank, B. A., Savage, C. H., Sorokin, A. V., Mehta, N. N., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-53603-6 · Cited by 85
Fialkow, J. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0170-7 · Cited by 80
“More recently, clinical trials of ezetimibe (IMPROVE-IT [82]) and proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors (OSLER study [83] and ODYSSEY LONG TERM study [84]) have confirmed or suggested that statin add-on therapy may be effective in further reducing residual cardiovascular risk.”
BackgroundSynthetic multi-layer nanoparticles for CRISPR-Cas9 genome editing
Tang, H., Zhao, X., & Jiang, X. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.03.001 · Cited by 83
Modulation of Glucokinase Regulatory Protein: A Double-Edged Sword?
Brouwers, M. C. G. J., Jacobs, C., Bast, A., Stehouwer, C. D. A., & Schaper, N. C. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.08.004 · Cited by 90
“For example, the cardioprotective effects of loss-of-function variants in proprotein subtilisin kexin type 9 (PCSK9) [81] – a protein involved in cholesterol metabolism – have recently been corroborated by two clinical trials with PCSK9 antagonists [82,83].”
Result
Metadata
- Authors
- Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., Koren, M. J., Lepor, N. E., Lorenzato, C., Pordy, R., Chaudhari, U., & Kastelein, J. J. P.
- Affiliations
- University of Iowa (US)
- Centre Hospitalier Universitaire de Nantes (FR)
- Université de Lille (FR)
- Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo (IT)
- Amsterdam UMC Location University of Amsterdam (NL)
- Oslo University Hospital (NO)
- University of the Witwatersrand (ZA)
- Jacksonville Center for Clinical Research (US)
- Westside Medical Associates of Los Angeles (US)
- Sanofi (France) (FR)
- Regeneron (United States) (US)
- Sanofi (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-04-16
- Volume
- 372
- Issue
- 16
- Pages
- 1489-1499
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2001328643
- Semantic Scholar
- 942bcfdc93b04ccb90a2d3e1df4c7950a45e92c2
- Cited by
- 2,296
- References
- 35
- Citations by year
- 2026: 67 · 2025: 103 · 2024: 150 · 2023: 141 · 2022: 134 · 2021: 159 · 2020: 165 · 2019: 226 · 2018: 251 · 2017: 339 · 2016: 369 · 2015: 183
- FWCI
- 383.69
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- alirocumab, PCSK9 inhibition, LDL cholesterol lowering, statin therapy, major adverse cardiovascular events, cardiovascular risk reduction, monoclonal antibodies, injection site reactions, high-risk patients, lipid-lowering therapy
- MeSH terms
- Aged, Antibodies, Monoclonal, Anticholesteremic Agents, Cardiovascular Diseases, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.